Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learning
Open accessThe DOI matches its Crossref record; 72 of the 74 references it cites were found in a registry or an index.
Abstract
Background: Metabolic dysfunction-associated steatohepatitis (MASH) is a highly prevalent liver disease globally, with a significant risk of progressing to cirrhosis and even liver cancer. Efferocytosis, a process implicated in a broad spectrum of chronic inflammatory disorders, has been reported to be associated with the pathogenesis of MASH; however, its precise role remains obscure. Thus, we aimed to identify and validate efferocytosis linked signatures for detection of MASH. Methods: We retrieved gene expression patterns of MASH from the GEO database and then focused on assessing the differential expression of efferocytosis-related genes (EFRGs) between MASH and control groups. This analysis was followed by a series of in-depth investigations, including protein–protein interaction (PPI), correlation analysis, and functional enrichment analysis, to uncover the molecular interactions and pathways at play. To screen for biomarkers for diagnosis, we applied machine learning algorithm to identify hub genes and constructed a clinical predictive model. Additionally, we conducted immune infiltration and single-cell transcriptome analyses in both MASH and control samples, providing insights into the immune cell landscape and cellular heterogeneity in these conditions. Results: This research pinpointed 39 genes exhibiting a robust correlation with efferocytosis in MASH. Among these, five potential diagnostic biomarkers— TREM2, TIMD4, STAB1, C1QC, and DYNLT1 —were screened using two distinct machine learning models. Subsequent external validation and animal experimentation validated the upregulation of TREM2 and downregulation of TIMD4 in MASH samples. Notably, both TREM2 and TIMD4 demonstrated area under the curve (AUC) values exceeding 0.9, underscoring their significant potential in facilitating the diagnosis of MASH. Conclusion: Our study comprehensively elucidated the relationship between MASH and efferocytosis, constructing a favorable diagnostic model. Furthermore, we identified potential therapeutic targets for MASH treatment and offered novel insights into unraveling the underlying mechanisms of this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These data are consistent with data in the Gene Expression Omnibus dataset GSE126848 showing that TIMD4 mRNA is lower in human MASH versus control liver (35).”
From Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis (2025) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.115.001593 · Cited by 3,466
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390 · cited 1×
“MYC is an oncogenic transcription factor, overexpressed in many malignancies and linked to aggressive tumor progression and poor survival outcomes (62).”
BackgroundNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Self-citationFadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, D. L., & Henson, P. M. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.7.2207 · Cited by 3,316
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100 · cited 1×
“Metabolic dysfunction-associated fatty liver disease (MASLD), formerly termed as non-alcoholic fatty liver disease (NAFLD), is the most prevalent chronic liver ailment, with a global incidence rate of approximately 30% (1, 2).”
BackgroundThe prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654
Identification of a factor that links apoptotic cells to phagocytes
Hanayama, R., Tanaka, M., Miwa, K., Shinohara, A., Iwamatsu, A., & Nagata, S. (2002) · Nature · doi:10.1038/417182a · Cited by 1,401 · cited 1×
“The second category comprises receptors that require bridge molecules to indirectly recognize PS, including growth arrest-speci fi c protein 6 (GAS6)/protein S for the TAM receptor family (24) and milk fat globule-EGF factor 8 (MFG-E8) for the a v b 3/5 integrins (25, 26).”
BackgroundNonalcoholic Steatohepatitis: A Review
Sheka, A. C., Adeyi, O., Thompson, J., Hameed, B., Crawford, P. A., & Ikramuddin, S. (2020) · JAMA · doi:10.1001/jama.2020.2298 · Cited by 1,379
Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner
Jaitin, D. A., Adlung, L., Thaiss, C. A., Weiner, A., Li, B., Descamps, H., Lundgren, P., Bleriot, C., Liu, Z., Deczkowska, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.054 · Cited by 1,377 · cited 1×
“While TREM2 ’ s role in glucose and lipid metabolism and its impact on disease onset and progression are well-documented (40, 55), its connection to amino acid metabolism remains unclear.”
BackgroundTREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease
Ulland, T. K., Song, W. M., Huang, S. C.-C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., Loboda, A. A., Zhou, Y., Cairns, N. J., Kambal, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.023 · Cited by 1,263 · cited 1×
“While TREM2 ’ s role in glucose and lipid metabolism and its impact on disease onset and progression are well-documented (40, 55), its connection to amino acid metabolism remains unclear.”
BackgroundNonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,198
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis
Chekeni, F. B., Elliott, M. R., Sandilos, J. K., Walk, S. F., Kinchen, J. M., Lazarowski, E. R., Armstrong, A. J., Penuela, S., Laird, D. W., Salvesen, G. S., et al. (2010) · Nature · doi:10.1038/nature09413 · Cited by 1,120
Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Emerging concepts of miRNA therapeutics: from cells to clinic
Diener, C., Keller, A., & Meese, E. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.006 · Cited by 971
Lauber, K., Bohn, E., Kröber, S. M., Xiao, Y.-J., Blumenthal, S. G., Lindemann, R. K., Marini, P., Wiedig, C., Zobywalski, A., Baksh, S., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00422-7 · Cited by 967
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
The clearance of dead cells by efferocytosis
Boada-Romero, E., Martinez, J., Heckmann, B. L., & Green, D. R. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0232-1 · Cited by 876
BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module
Park, D., Tosello-Trampont, A.-C., Elliott, M. R., Lu, M., Haney, L. B., Ma, Z., Klibanov, A. L., Mandell, J. W., & Ravichandran, K. S. (2007) · Nature · doi:10.1038/nature06329 · Cited by 849
SVM-RFE: selection and visualization of the most relevant features through non-linear kernels
Sanz, H., Valim, C., Vegas, E., Oller, J. M., & Reverter, F. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2451-4 · Cited by 804
An Apoptotic ‘Eat Me’ Signal: Phosphatidylserine Exposure
Segawa, K., & Nagata, S. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.08.003 · Cited by 783
TIM-1 and TIM-4 Glycoproteins Bind Phosphatidylserine and Mediate Uptake of Apoptotic Cells
Kobayashi, N., Karisola, P., Peña-Cruz, V., Dorfman, D. M., Jinushi, M., Umetsu, S. E., Butte, M. J., Nagumo, H., Chernova, I., Zhu, B., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.011 · Cited by 642
Self-citationZhang, S., Weinberg, S., DeBerge, M., Gainullina, A., Schipma, M., Kinchen, J. M., Ben-Sahra, I., Gius, D. R., Yvan-Charvet, L., Chandel, N. S., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.12.004 · Cited by 485
Drugging the efferocytosis process: concepts and opportunities
Mehrotra, P., & Ravichandran, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00470-y · Cited by 459 · cited 2×
“Efferocytosis, the physiological process whereby phagocytes engulf and eliminate apoptotic cells, has garnered signi fi cant research attention due to its role in cardiovascular diseases, ischemic stroke, and cancer (10, 12, 37, 38).”
BackgroundMachine learning for precision medicine
MacEachern, S. J., & Forkert, N. D. (2021) · Genome · doi:10.1139/gen-2020-0131 · Cited by 455
Seidman, J. S., Troutman, T. D., Sakai, M., Gola, A., Spann, N. J., Bennett, H., Bruni, C. M., Ouyang, Z., Li, R. Z., Sun, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.001 · Cited by 443
Colonna, M. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00837-1 · Cited by 394 · cited 2×
“TREM2 is an activating receptor highly expressed in tissue macrophages, responsible for detecting apoptotic cells by recognizing exposed phospholipids (39).”
BackgroundResultGude, D. R., Alvarez, S. E., Paugh, S. W., Mitra, P., Yu, J., Griffiths, R., Barbour, S. E., Milstien, S., & Spiegel, S. (2008) · The FASEB Journal · doi:10.1096/fj.08-107169 · Cited by 364
Efferocytosis induces macrophage proliferation to help resolve tissue injury
Gerlach, B. D., Ampomah, P. B., Yurdagul, A., Liu, C., Lauring, M. C., Wang, X., Kasikara, C., Kong, N., Shi, J., Tao, W., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.10.015 · Cited by 360
Simon, T. G., Roelstraete, B., Hagström, H., Sundström, J., & Ludvigsson, J. F. (2022) · Gut · doi:10.1136/gutjnl-2021-325724 · Cited by 321
The Dynamics of Apoptotic Cell Clearance
Elliott, M. R., & Ravichandran, K. S. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.06.029 · Cited by 319
Oxidative phosphorylation selectively orchestrates tissue macrophage homeostasis
Wculek, S. K., Heras-Murillo, I., Mastrangelo, A., Mañanes, D., Galán, M., Miguel, V., Curtabbi, A., Barbas, C., Chandel, N. S., Enríquez, J. A., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.011 · Cited by 307
Macrophage phenotypes and functions: resolving inflammation and restoring homeostasis
Rodríguez-Morales, P., & Franklin, R. A. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.10.004 · Cited by 304
SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease
Shin, J., He, M., Liu, Y., Paredes, S., Villanova, L., Brown, K., Qiu, X., Nabavi, N., Mohrin, M., Wojnoonski, K., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.007 · Cited by 287 · cited 1×
“MYC has also been identi fi ed as a promising therapeutic target for MASLD (67, 68).”
BackgroundSelf-citationSuppli, M. P., Rigbolt, K. T. G., Veidal, S. S., Heebøll, S., Eriksen, P. L., Demant, M., Bagger, J. I., Nielsen, J. C., Oró, D., Thrane, S. W., et al. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00358.2018 · Cited by 282
(2006) · Hepatology · doi:10.1002/(issn)1527-3350 · Cited by 262
Wang, X., He, Q., Zhou, C., Xu, Y., Liu, D., Fujiwara, N., Kubota, N., Click, A., Henderson, P., Vancil, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2022.11.013 · Cited by 262
Therapies in non‐alcoholic steatohepatitis (NASH)
Oseini, A. M., & Sanyal, A. J. (2017) · Liver International · doi:10.1111/liv.13302 · Cited by 235
Akakura, S., Singh, S., Spataro, M., Akakura, R., Kim, J.-I., Albert, M. L., & Birge, R. B. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2003.09.011 · Cited by 230
Ampomah, P. B., Cai, B., Sukka, S. R., Gerlach, B. D., Yurdagul, A., Wang, X., Kuriakose, G., Darville, L. N. F., Sun, Y., Sidoli, S., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00551-7 · Cited by 173
Kim, K.-S., Hong, S., Han, K., & Park, C.-Y. (2024) · BMJ · doi:10.1136/bmj-2023-076388 · Cited by 173
Activation of the complement system in human nonalcoholic fatty liver disease†
Rensen, S. S., Slaats, Y., Driessen, A., Peutz‐Kootstra, C. J., Nijhuis, J., Steffensen, R., Greve, J. W., & Buurman, W. A. (2009) · Hepatology · doi:10.1002/hep.23228 · Cited by 165
The Phosphatidylserine Receptor TIM-4 Does Not Mediate Direct Signaling
Park, D., Hochreiter-Hufford, A., & Ravichandran, K. S. (2009) · Current Biology · doi:10.1016/j.cub.2009.01.042 · Cited by 161
Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis
Kojima, Y., Downing, K., Kundu, R., Miller, C., Dewey, F., Lancero, H., Raaz, U., Perisic, L., Hedin, U., Schadt, E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70391 · Cited by 148
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Xia, H., Li, S., Li, X., Wang, W., Bian, Y., Wei, S., Grove, S., Wang, W., Vatan, L., Liu, J. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.141115 · Cited by 137
Shen, Y., Cheng, L., Xu, M., Wang, W., Wan, Z., Xiong, H., Guo, W., Cai, M., & Xu, F. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155657 · Cited by 117
First we eat, then we do everything else: The dynamic metabolic regulation of efferocytosis
Trzeciak, A., Wang, Y.-T., & Perry, J. S. A. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.08.001 · Cited by 99
Ngai, D., Schilperoort, M., & Tabas, I. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00921-9 · Cited by 95
Jeong, B.-K., Choi, W., Choi, W., Moon, J., Lee, W. H., Choi, C., Choi, I. Y., Lee, S.-H., Kim, P., Ju, Y. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50660-y · Cited by 90
MYC amplifies gene expression through global changes in transcription factor dynamics
Patange, S., Ball, D. A., Wan, Y., Karpova, T. S., Girvan, M., Levens, D., & Larson, D. R. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110292 · Cited by 86
DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates
Qu, P., Rom, O., Li, K., Jia, L., Gao, X., Liu, Z., Ding, S., Zhao, M., Wang, H., Chen, S., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.03.013 · Cited by 83
Self-citationLive cell tracking of macrophage efferocytosis during Drosophila embryo development in vivo
Raymond, M. H., Davidson, A. J., Shen, Y., Tudor, D. R., Lucas, C. D., Morioka, S., Perry, J. S. A., Krapivkina, J., Perrais, D., Schumacher, L. J., et al. (2022) · Science · doi:10.1126/science.abl4430 · Cited by 82
Indira Chandran, V., Wernberg, C. W., Lauridsen, M. M., Skytthe, M. K., Bendixen, S. M., Larsen, F. T., Hansen, C. D., Grønkjær, L. L., Siersbæk, M. S., Caterino, T. D., et al. (2023) · Hepatology · doi:10.1002/hep.32620 · Cited by 62
Myc‐nick promotes efferocytosis through M2 macrophage polarization during resolution of inflammation
Zhong, X., Lee, H., Kim, S. H., Park, S., Kim, W., Cha, Y., & Surh, Y. (2018) · The FASEB Journal · doi:10.1096/fj.201800223r · Cited by 61
Efferocytosis in the Central Nervous System
Zhao, J., Zhang, W., Wu, T., Wang, H., Mao, J., Liu, J., Zhou, Z., Lin, X., Yan, H., & Wang, Q. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.773344 · Cited by 57
Efferocytosis: An accomplice of cancer immune escape
Qiu, H., Shao, Z., Wen, X., Liu, Z., Chen, Z., Qu, D., Ding, X., & Zhang, L. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115540 · Cited by 51
Teimouri, M., Hosseini, H., Shabani, M., Koushki, M., Noorbakhsh, F., & Meshkani, R. (2020) · IUBMB Life · doi:10.1002/iub.2221 · Cited by 48
Cheng, W., Li, M., Zhang, L., Zhou, C., Yu, S., Peng, X., Zhang, W., & Zhang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.973116 · Cited by 47
Macrophagic Stabilin-1 Restored Disruption of Vascular Integrity Caused by Sepsis
Lee, W., Park, S.-Y., Yoo, Y., Kim, S.-Y., Kim, J.-E., Kim, S.-W., Seo, Y.-K., Park, E., Kim, I.-S., & Bae, J.-S. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1669477 · Cited by 45
Tim4 Recognizes Carbon Nanotubes and Mediates Frustrated Phagocytosis Leading to Granuloma Formation
Omori, S., Tsugita, M., Hoshikawa, Y., Morita, M., Ito, F., Yamaguchi, S.-I., Xie, Q., Noyori, O., Yamaguchi, T., Takada, A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.108734 · Cited by 38
Efferocytosis of vascular cells in cardiovascular disease
Cabrera, J. T. O., & Makino, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107919 · Cited by 37
S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma
Delangre, E., Oppliger, E., Berkcan, S., Gjorgjieva, M., de Sousa, M. C., & Foti, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911030 · Cited by 33
Macrophage Heterogeneity in NASH: More Than Just Nomenclature
Parthasarathy, G., & Malhi, H. (2021) · Hepatology · doi:10.1002/hep.31790 · Cited by 23
Bae, D.-J., Seo, J., Kim, S.-Y., Park, S., Pyo, J.-H., Pyo, J.-H., Cho, W., Cho, J.-Y., Kim, S., & Kim, I. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.07.003 · Cited by 20
Zhao, P., Wang, H., Li, T., Lei, C., Xu, X., Wang, W., Liang, X., Ma, C., & Gao, L. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12276 · Cited by 15
Cited by
Shi, H., Wang, X., Sloas, C., Gerlach, B., Yurdagul, A., Moore, M. P., Jung, E. J., Mirshahi, F., Ronzoni, L., Sanyal, A. J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adv2106 · Cited by 30
Li, Y., Li, P., Song, J., Zhang, X., Xiao, H., Wang, R., Duan, Z., Luo, K., & 徐学文 (2026) · Theranostics · doi:10.7150/thno.126081 · Cited by 27
Chen, Y., Bian, S., & Le, J. (2025) · Genes · doi:10.3390/genes16040399 · Cited by 13
Self-citationLiao, J., Zhou, Z., Lv, Y., Zhang, Y., Liu, S., Tang, H., Qv, F., Wang, S., Yang, L., Lu, Y., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1667180 · Cited by 9
Self-citationUncovering the Molecular Networks of Extracellular Vesicles in the Pathogenesis of Periodontitis
Yu, W., Huoshen, W., Zhong, W., Gao, X. Y., & Song, J. (2025) · International Dental Journal · doi:10.1016/j.identj.2025.103936 · Cited by 2
Metadata
- Authors
- Cao, C., Liu, W., Guo, X., Weng, S., Chen, Y., Luo, Y., Wang, S., Zhu, B., Liu, Y., & Peng, D.
- Affiliations
- Central South University (CN)
- Corresponding author
- Peng, Daoquan
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2024-10-21
- Volume
- 15
- Pages
- 1460431-1460431
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC11532026
- OpenAlex
- W4403583736
- Cited by
- 16
- References
- 74
- Citations by year
- 2026: 9 · 2025: 7
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81870336, 81600359)
- Xiangya Hospital, Central South University
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- nonalcoholic steatohepatitis, efferocytosis, diagnostic biomarkers, TREM2, TIMD4, hub genes, immune cell infiltration, single-cell transcriptome, liver disease diagnosis, therapeutic target
- MeSH terms
- Machine Learning, Efferocytosis, Animals, Fatty Liver, Humans, Phagocytosis, Biomarkers, Computational Biology, Gene Expression Profiling, Transcriptome, Protein Interaction Maps
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.